Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) shares dropped 1.4% during mid-day trading on Tuesday . The stock traded as low as $369.59 and last traded at $370.51, with a volume of 339,886 shares traded. The stock had previously closed at $375.74.

Several brokerages recently weighed in on REGN. Chardan Capital cut Regeneron Pharmaceuticals from a “neutral” rating to a “sell” rating and decreased their target price for the company from $375.00 to $325.00 in a research note on Wednesday, March 16th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and set a $506.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, March 18th. Zacks Investment Research cut Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 target price (down previously from $525.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 31st. Finally, Brean Capital reaffirmed a “buy” rating and set a $489.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 15th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $508.32.

The stock has a market capitalization of $38.46 billion and a P/E ratio of 58.47. The firm has a 50 day moving average price of $372.18 and a 200-day moving average price of $401.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.58 by $0.01. During the same quarter last year, the firm earned $2.88 EPS. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.18 billion. Regeneron Pharmaceuticals’s revenue for the quarter was up 38.0% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals Inc. will post $10.86 earnings per share for the current fiscal year.

In related news, major shareholder Sanofi purchased 64,731 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, June 14th. The shares were bought at an average cost of $363.86 per share, for a total transaction of $23,553,021.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $396.64, for a total transaction of $396,640.00. Following the completion of the sale, the director now owns 40,500 shares in the company, valued at $16,063,920. The disclosure for this sale can be found here.

Several institutional investors have modified their holdings of the company. Financial Counselors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 5.3% in the fourth quarter. Financial Counselors Inc. now owns 1,846 shares of the biopharmaceutical company’s stock worth $1,002,000 after buying an additional 93 shares during the last quarter. Brown Advisory Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Brown Advisory Inc. now owns 1,920 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 58 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 106.2% in the fourth quarter. Victory Capital Management Inc. now owns 2,072 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 1,067 shares during the last quarter. Stephens Inc. AR boosted its position in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Stephens Inc. AR now owns 2,488 shares of the biopharmaceutical company’s stock worth $1,351,000 after buying an additional 190 shares during the last quarter. Finally, Private Advisor Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 17.4% in the fourth quarter. Private Advisor Group LLC now owns 2,506 shares of the biopharmaceutical company’s stock worth $1,360,000 after buying an additional 371 shares during the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.